β-Blockers in COPD  by Galal, Iman
Egyptian Journal of Chest Diseases and Tuberculosis (2014) 63, 277–278Egyptian Journal of Chest Diseases and Tuberculosis
Egyptian Journal of Chest Diseases and Tuberculosis
www.elsevier.com/locate/ejcdt
www.sciencedirect.comEDITORIALb-Blockers in COPDIntroduction
b-Blockers were frequently withheld in patients with chronic
obstructive pulmonary disease (COPD) because of concerns
that they might diminish the bronchodilator effect of b2 ago-
nists and aggravate bronchospastic symptoms.1,2 This assump-
tion might have for long deprived many of the COPD patients
with substantial cardiovascular comorbidity from the beneﬁ-
cial cardiovascular effect of b-blockers.
Although a Cochrane meta-analysis concluded that b-1
selective b blockade was safe,3,4 patients with COPD have half
the odds of being treated with b-blockers during acute myocar-
dial infarction (MI) than those without COPD5 and only 35%
of patients with congestive heart failure (CHF) and COPD
receive b-blocker therapy.6,7
Several observational studies have examined the potential
risks and beneﬁts of b-blocker use in COPD. Most studies, to
date, have looked at b-blocker use during the usual course of
COPD without speciﬁcally examining their risk or beneﬁt at
the time of an acute exacerbation of COPD (AECOPD).8–11
Physicians may be even more reluctant to continue b-blocker
therapy during AE-COPD when a patient’s respiratory status
is most tenuous. During an AE-COPD, patients may be partic-
ularly vulnerable to develop acute cardiac events12 due to in-
creased use of b2 agonists, tachycardia and hypoxaemia. The
addition of a cardioselective b-blocker may have a cardiopro-
tective effect in this population, blunting the cardiac toxicity
of the b2 agonists.
Stefan et al.13 in his study address the question of the effects
of b-blockers given early to patients hospitalised for serious
AECOPD who also have ischaemic heart disease or heart fail-
ure. The paper reported that the 29% of patients who received
b-blockers during the ﬁrst 2 days of the hospital stay did not
have an increased risk of in-hospital mortality, readmission
within 30 days, or mechanical ventilation, compared with
COPD patients who did not receive b-blockers. The resultsPeer review under responsibility of The Egyptian Society of Chest
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it is one of the ﬁrst studies to highlight the effects of b-blockers
during a serious exacerbation requiring hospitalisation. This is
a particularly crucial time, as COPD exacerbations are associ-
ated with high mortality in the ﬁrst 1–2 weeks,14 which is likely
more if the patients also have cardiovascular comorbidity.
Thus, the use or non-use of b-blockers during the ﬁrst 2 days
of hospitalisation may be a marker of speciﬁc health status
that would dictate continuation or discontinuation of these
drugs early in the hospitalisation. This study suggests that b-
blockers are safe during this particularly high-risk period.
Yet, the assumption that a single day or 2 of b-blockers can
actually impact on lung function and mortality is still
uncertain.
Future studies should investigate the effects as a function of
duration of exposure, since bronchospasm may be more likely
to occur once concomitant therapy changes over the course of
hospitalisation, for instance, after a reduction in the dose of
bronchodilators.15
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